Medicare Part D price protection may be on its last legs for seniors.
That's according to the Center for Retirement Research at Boston College, which singled out research from the Kaiser Family Foundation on price spikes for specialty drugs as a threat to seniors' ability to manage their out-of-pocket drug spending.
Price hikes on drugs were a major source of headlines during 2015, with former Turing Pharmaceuticals CEO Martin Shkreli coming in for a firestorm of criticism after his company increased the price on Daraprim, a drug used by cancer and AIDS patients by 5,000 percent.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
